Giant Biogene FY26 H1 net profit drops 20.5% to RMB 939.5 million; revenue falls 6.3% to RMB 2.92 billion

• Giant Biogene posted IFRS net profit of RMB 939.5 million, down 20.5% year over year; revenue fell 6.3% to RMB 2.92 billion.
• Basic earnings per share slid 21.9% to RMB 0.89; gross profit declined 8.8% to RMB 2.32 billion.
• Selling and distribution expenses rose 19.7% to RMB 1.27 billion; profit before taxation dropped 24.2% to RMB 1.1 billion.
• Direct sales generated RMB 2.23 billion, representing 76.6% of revenue; distributor sales decreased 13.2% to RMB 683.3 million.
• Management cited a strategic sales restructuring in professional skin treatment products; it targets a return to full-year growth in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Giant Biogene Holding Co Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260818-12288845), on August 18, 2026, and is solely responsible for the information contained therein.